Worth reading
50Recurring
Scored from 5 of 6 sectionsDirection
Mixed performance
Direction inferred from the company’s description.Scale
26.4
% (year-on-year change in net sales)Wording
Conditional
How definitive the wording is.Results for this period
First quarter2025年4月1日〜2025年6月30日ConsolidatedJapanese GAAPNet Sales2,552¥ millionYear on year +26.4%Progress 23.2%
Operating profit71¥ millionYear on year -29.7%Progress 11.6%
Ordinary income54¥ millionYear on year -45.0%Progress 9.6%
Net income attributable to owners of the parent-22¥ million
The width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
Net income per share△4.71円
Financial position at period-end
Total assets10,279¥ million
of which net assets 3,550 ¥ millionEquity ratio 33.1%vs. prior year-end -0.7pt
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Segment revenue
Medical Business576,67722.6%+38,124.0%
Platform Business831,95632.6%+3.4%
Broadband business906,41735.5%-3.3%
SaaS and DX Business238,8939.4%-0.8%
Segment profit
Medical Business-41,030+7,414.0%
Platform Business68,368-45.1%
Broadband business139,266-5.1%
SaaS and DX Business-15,603+14,507.0%
Outlook and shareholder returns
Full-year earnings forecast
Net Sales¥11,000 million (YoY +21.0%)
Operating profit¥610 million (YoY +30.9%)
Ordinary income¥560 million (YoY +57.8%)
Net income¥320 million (YoY +73.8%)
Annual Dividend Forecast¥30 → ¥31.5（+5.0%）
Factors Behind Changes in Business Performance
メディカル事業では診療科目の拡大と積極的なプロモーションにより増収となった。プラットフォーム事業ではメディアサービスの広告単価下落、ブロードバンド事業では課金会員数の伸び悩み、SaaS・DX事業ではDXサービスの減収が業績に影響した。
Disclosure regarding the going concern assumption
No applicable matters
Change in accounting policy
基準改正に伴う変更 Noneそれ以外の変更 None見積りの変更 None修正再表示 None
Changes in the scope of consolidationNew 0 companies / Excluded 0 companies / Company name None
Material subsequent eventsNo applicable matters
Impairment lossNo applicable matters
Breakdown of extraordinary income (loss)Extraordinary income Gain on sale of property, plant and equipment ¥12,920 thousand / Extraordinary loss Head Office Relocation Costs ¥68,690 thousand, Business Exit Losses ¥33,135 thousand, Other ¥0 thousand
Depreciation and amortization¥7,916 thousand
Availability of Supplementary Financial Results MaterialsYes
Availability of Financial Results BriefingAvailable (for institutional investors and analysts)
Issued Shares at Period-End4,865,630株
Treasury Shares at Period-End— shares
| Item | Details |
|---|---|
| Fiscal Period Classification | First quarter |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Consolidated |
| Period Covered | 2025年4月1日〜2025年6月30日 |
| Net Sales | ¥2,552 million (YoY +26.4%) |
| Operating profit | ¥71 million (YoY -29.7%) |
| Ordinary income | ¥54 million (YoY -45.0%) |
| Profit attributable to owners of the parent | ¥-22 million |
| Net income per share | △4.71円 |
| Equity ratio | End of the current fiscal period 33.1 / End of previous period 33.8 |
| Total assets | ¥10,279 million |
| Net assets | ¥3,550 million |
| Full-year earnings forecast | Net Sales ¥11,000 million (YoY +21.0%) / Operating profit ¥610 million (YoY +30.9%) / Ordinary income ¥560 million (YoY +57.8%) / Net income ¥320 million (YoY +73.8%) |
| Annual Dividend Forecast | ¥30 → ¥31.5（+5.0%） |
| Segment revenue | Segment Medical Business / Net Sales ¥576,677 thousand / Year on year against the same period last year 前年同期間38,124千円, Segment Platform Business / Net Sales ¥831,956 thousand / Year on year against the same period last year 3.4, Segment Broadband business / Net Sales ¥906,417 thousand / Year on year against the same period last year -3.3, Segment SaaS and DX Business / Net Sales ¥238,893 thousand / Year on year against the same period last year -0.8 |
| Segment profit | Segment Medical Business / Segment profit ¥-41,030 thousand / Year on year against the same period last year 前年同期間7,414千円の損失, Segment Platform Business / Segment profit ¥68,368 thousand / Year on year against the same period last year -45.1, Segment Broadband business / Segment profit ¥139,266 thousand / Year on year against the same period last year -5.1, Segment SaaS and DX Business / Segment profit ¥-15,603 thousand / Year on year against the same period last year 前年同期間14,507千円の損失 |
| Depreciation and amortization | ¥7,916 thousand |
| Impairment loss | No applicable matters |
| Breakdown of extraordinary income (loss) | Extraordinary income Gain on sale of property, plant and equipment ¥12,920 thousand / Extraordinary loss Head Office Relocation Costs ¥68,690 thousand, Business Exit Losses ¥33,135 thousand, Other ¥0 thousand |
| Disclosure regarding the going concern assumption | No applicable matters |
| Change in accounting policy | Changes due to revisions to standards None / Other changes None / Change in accounting estimate None / Restatement None |
| Changes in the scope of consolidation | New 0 companies / Excluded 0 companies / Company name None |
| Material subsequent events | No applicable matters |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Available (for institutional investors and analysts) |
| Issued Shares at Period-End | 4,865,630株 |
| Treasury Shares at Period-End | — shares |
| Factors Behind Changes in Business Performance | メディカル事業では診療科目の拡大と積極的なプロモーションにより増収となった。プラットフォーム事業ではメディアサービスの広告単価下落、ブロードバンド事業では課金会員数の伸び悩み、SaaS・DX事業ではDXサービスの減収が業績に影響した。 |
Items this document does not state (10)
Operating MarginCash flows from operating activitiesCash flows from investing activitiesCash flows from financing activitiesCash and cash equivalents at end of periodRevision to Earnings ForecastPayout ratioShareholder Return PolicyRegional salesOrders received and order backlog
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.メディカル事業では診療科目が拡大し、大幅な増収となった。一方、メディアサービスでは広告単価が下落し、売上高と営業利益に悪影響を及ぼした。また、本社移転費用等を特別損失に計上した。
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.